---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-253851"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2026-06-02T21:15:12+00:00"
generated_at: "2026-06-02T21:16:26.383586+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Court invalidates two CINVANTI patents; Heron to appeal to Federal Circuit

## Summary
- U.S. District Court for Delaware ruled claims of Patents 12,115,255 and 12,290,520 invalid on June 1, 2026.
- Decision does not affect prior settlements for CINVANTI or APONVIE injectable emulsions.
- Heron intends to appeal to the Federal Circuit, a court specializing in patent disputes.
- CEO Craig Collard said company will vigorously pursue appeal and all available remedies.
- Litigation with Azurity (formerly Slayback) involves a generic version of CINVANTI.

## SEC filing metadata
- accession: 0001193125-26-253851
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2026-06-02T21:15:12+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000119312526253851/0001193125-26-253851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000119312526253851/hrtx-20260602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-253851
- JSON: https://secwatch.observer/filing/0001193125-26-253851.json
- Plain text: https://secwatch.observer/filing/0001193125-26-253851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.